US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
pharma · Focal Segmental Glomerulosclerosis · Immunoglobulin A Nephropathy (IgAN) · TVTX
Travere Therapeutics
Travere Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US HQ
2020 Founded
506 Employees
Public company Type
TVTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US
- Founded
- 2020
- Employees
- 506
- Programs
- 13
- Drugs
- 9
- Patents
- 1
Travere Therapeutics pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Travere Therapeutics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Travere Therapeutics in public FDA and regional records.
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
irbesartan
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
Development asset linked to Travere Therapeutics in public FDA and regional records.
-
Development asset linked to Travere Therapeutics in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Travere Therapeutics in public FDA and regional records.
-
sparsentan
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Endothelin-1 receptor.
- Target
- Endothelin-1 receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist